Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 1,000 shares at $293.34 ($290K) on 2015-03-27, disclosed to the SEC on 2015-04-01.
Open-market sale of $290k ICPT by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $285.00 | 100 | $29K | 9.8% |
| 2 | $286.00 | 100 | $29K | 9.9% |
| 3 | $287.00 | 100 | $29K | 9.9% |
| 4 | $288.00 | 100 | $29K | 9.9% |
| 5 | $289.00 | 100 | $29K | 10.0% |
| 6 | $291.00 | 100 |
| $29K |
| 10.0% |
| 7 | $292.16 | 100 | $29K | 10.1% |
| 8 | $293.34 | 300 | $88K | 30.4% |
| Total | $289.82 avg | 1,000 | $290K | 100% |
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |